<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1-5396-19
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        GEMZAR 200MG LYPH.VIAL 5ML
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        GEMCITABINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        142.6
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Vianex S.A. &#x2013; Plant C " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Vianex S.A. – Plant C 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            LILLY FRANCE 
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01BC05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Gemzar belongs to a group of medicines called &ldquo;cytotoxics&rdquo;. These medicines kill dividing cells, including cancer cells.</p><p>Gemzar may be given alone or in combination with other anti-cancer medicines, depending on the type of cancer.</p><p>Gemzar is used in the treatment of the following types of cancer:</p><ul><li>non-small cell lung cancer (NSCLC), alone or together with cisplatin</li><li>pancreatic cancer.</li><li>breast cancer, together with paclitaxel.</li><li>ovarian cancer, together with carboplatin.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Gemzar</strong></p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic (hypersensitive) to gemcitabine or any of the other ingredients of this medicine (listed in section 6).</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are breast-feeding</p><p><strong>Warnings and Precautions</strong></p><p>Before the first infusion you will have samples of your blood taken to check if your liver and kidneys are working well enough for you to receive this medicine. Before each infusion you will have samples of your blood taken to check if you have enough blood cells to receive Gemzar. Your doctor may decide to change the dose or delay treating you depending on your general condition and if your blood cell counts are too low. Periodically you will have samples of your blood taken to check how well your kidneys and liver are working.</p><p>Talk to your doctor, nurse or hospital pharmacist before using Gemzar</p><p>If you have, or have previously had liver disease, heart disease, vascular disease or problems with your kidneys talk to your doctor or hospital pharmacist as you may not be able to receive Gemzar.</p><p>If you have recently had, or are going to have radiotherapy, please tell your doctor as there may be an early or late radiation reaction with Gemzar.</p><p>If you have been vaccinated recently, please tell your doctor as this can possibly cause bad effects with Gemzar.</p><p>If during treatment with this medicine, you get symptoms such as headache with confusion, seizures (fits) or changes in vision, call your doctor right away. This could be a very rare nervous system side effect named posterior reversible encephalopathy syndrome.</p><p>If you develop breathing difficulties or feel very weak and are very pale, please tell your doctor as this may be a sign of kidney failure or problems with your lungs.</p><p>If you develop generalised swelling, shortness of breath or weight gain, please tell your doctor as this may be a sign of fluid leaking from your small blood vessels into the tissue.</p><p><strong>Children and adolescents</strong></p><p>This medicine is not recommended for use in children under 18 years of age due to insufficient data on safety and efficacy.</p><p><strong>Other medicines and Gemzar</strong></p><p>Tell your doctor or hospital pharmacist if you are taking, have recently taken or might take any other medicines, including vaccinations and medicines obtained without a prescription.</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p><strong>Pregnancy</strong></p><p>If you are pregnant, or thinking about becoming pregnant, tell your doctor. The use of Gemzar should be avoided during pregnancy. Your doctor will discuss with you the potential risk of taking Gemzar during pregnancy. Women of childbearing age should use effective contraception during treatment with Gemzar and for 6 months after receiving the last dose.</p><p><strong>Breast-feeding</strong></p><p>If you are breast‑feeding, tell your doctor.</p><p>You must discontinue breast‑feeding during Gemzar treatment.</p><p><strong>Fertility</strong></p><p>Men are advised not to father a child during and up to 3 months following treatment with Gemzar and should therefore use effective contraception during treatment with Gemzar and for up to 3 months afterwards. If you would like to father a child during the treatment or in the 3 months following treatment, seek advice from your doctor or pharmacist. You may want to seek counselling on sperm storage before starting your therapy.</p><p><strong>Driving and using machines</strong></p><p>Gemzar may make you feel sleepy, particularly if you have consumed any alcohol. Do not drive a car or use machinery until you are sure that Gemzar treatment has not made you feel sleepy.</p><p><strong>Gemzar contains sodium</strong></p><p>Gemzar contains 3.5&nbsp;mg&nbsp;(&lt; 1 mmol) of sodium in each 200&nbsp;mg vial and 17.5&nbsp;mg (&lt; 1 mmol) sodium in each 1000&nbsp;mg vial ie essentially sodium free.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The usual dose of Gemzar is 1000‑1250&nbsp;mg for every square metre of your body&rsquo;s surface area. Your height and weight are measured to work out the surface area of your body. Your doctor will use this body surface area to work out the right dose for you. This dosage may be adjusted, or treatment may be delayed depending on your blood cell counts and on your general condition.</p><p>How frequently you receive your Gemzar infusion depends on the type of cancer that you are being treated for.</p><p>A hospital pharmacist or doctor will have dissolved the Gemzar powder before it is given to you.</p><p>You will always receive Gemzar by infusion into one of your veins. The infusion will last approximately 30 minutes.</p><p>If you have further questions on the use of this product ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Gemzar can cause side effects, although not everybody gets them.</p><p><strong>You must contact your doctor immediately if you notice any of the following:</strong></p><p>-&nbsp;&nbsp;&nbsp; Bleeding from the gums, nose or mouth or any bleeding that would not stop, reddish or pinkish urine, unexpected bruising (since you might have less platelets than normal which is very common).</p><p>-&nbsp;&nbsp;&nbsp; Tiredness, feeling faint, becoming easily breathless or if you look pale (since you might have less haemoglobin than normal which is very common).</p><p>-&nbsp;&nbsp;&nbsp; Mild to moderate skin rash (very common)&nbsp;/&nbsp;itching (common), or fever (very common); (allergic reactions).</p><p>-&nbsp;&nbsp;&nbsp; Temperature of 38&ordm;C or greater, sweating or other signs of infection (since you might have less white blood cells than normal accompanied by fever also known as febrile neutropenia) (common).</p><p>-&nbsp;&nbsp;&nbsp; Pain, redness, swelling or sores in your mouth (stomatitis) (common).</p><p>-&nbsp;&nbsp;&nbsp; Irregular heart rate (arrhythmia) (uncommon)</p><p>-&nbsp;&nbsp;&nbsp; Extreme tiredness and weakness, purpura or small areas of bleeding in the skin (bruises), acute renal failure (low urine output /or no urine output), and signs of infection (haemolytic uraemic syndrome). It may be fatal (uncommon).</p><p>-&nbsp;&nbsp;&nbsp; Difficulty breathing (it is common to have mild breathing difficulty soon after the Gemzar infusion which soon&nbsp;passes, however uncommonly or rarely there can be more severe lung problems)</p><p>-&nbsp;&nbsp;&nbsp; Severe chest pain (myocardial infarction) (rare).</p><p>-&nbsp;&nbsp;&nbsp; Severe hypersensitivity/allergic reaction with severe skin rash including red itchy skin, swelling of the hands, feet, ankles, face, lips, mouth or throat (which may cause difficulty in swallowing or breathing), wheezing, fast beating heart and you may feel you are going to faint (anaphylactic reaction)&nbsp;(very rare).</p><p>-&nbsp;&nbsp;&nbsp; Generalised swelling, shortness of breath or weight gain, as you might have fluid leakage from small blood vessels into the tissues (capillary leak syndrome) (very rare)</p><p>-&nbsp;&nbsp;&nbsp; Headache with changes in vision, confusion, seizures or fits (posterior reversible encephalopathy syndrome) (very rare)</p><p>-&nbsp;&nbsp;&nbsp; Severe rash with itching, blistering or peeling of the skin (Stevens-Johnson syndrome, toxic epidermal necrolysis) (very rare).</p><p>-&nbsp;&nbsp;&nbsp; Extreme tiredness and weakness, purpura or small areas of bleeding in the skin (bruises), acute renal failure (low urine output or no urine output), and signs of infection. These may be features of thrombotic microangiopathy (clots forming in small blood vessels) and haemolytic uraemic syndrome, which may be fatal.</p><p>&nbsp;</p><p><strong>Other side effects with Gemzar may include:</strong></p><p><strong>Very common side effects </strong>(may affect more than 1 in 10 people)</p><p>Low white blood cells</p><p>Difficulty breathing</p><p>Vomiting</p><p>Nausea</p><p>Hair loss</p><p>Liver problems: found through abnormal blood test results</p><p>Blood in urine</p><p>Abnormal urine tests: protein in urine</p><p>Flu like symptoms including fever</p><p>Swelling of ankles, fingers, feet, face (oedema)</p><p>&nbsp;</p><p><strong>Common side effects </strong>(may affect up to 1 in 10 people)</p><p>Poor appetite (anorexia)</p><p>Headache</p><p>Insomnia</p><p>Sleepiness</p><p>Cough</p><p>Runny nose</p><p>Constipation</p><p>Diarrhoea</p><p>Itching</p><p>Sweating</p><p>Muscle pain</p><p>Back pain</p><p>Fever</p><p>Weakness</p><p>Chills</p><p>Infections</p><p>&nbsp;</p><p><strong>Uncommon side effects </strong>(may affect up to 1 in 100 people)</p><p>Scarring of the air sacs of the lung (interstitial pneumonitis)</p><p>Wheeze (spasm of the airways)</p><p>Scarring of the lungs (abnormal chest X ray/scan)</p><p>Heart failure</p><p>Kidney failure</p><p>Serious liver damage, including liver failure</p><p>Stroke</p><p>&nbsp;</p><p><strong>Rare side effects </strong>(may affect up to 1 in 1,000 people)</p><p>Low blood pressure</p><p>Skin scaling, ulceration or blister formation</p><p>Sloughing of the skin and severe skin blistering</p><p>Injection site reactions</p><p>Severe lung inflammation causing respiratory failure (adult respiratory distress syndrome)</p><p>A skin rash like severe sunburn which can occur on skin that has previously been exposed to radiotherapy (radiation recall).</p><p>Fluid in the lungs</p><p>Scarring of the air sacs of the lung associated with radiation therapy (radiation toxicity)</p><p>Gangrene of fingers or toes</p><p>Inflammation of the blood vessels (peripheral vasculitis)</p><p>&nbsp;</p><p><strong>Very rare side effects </strong>(may affect up to 1 in 10,000 people)</p><p>Increased platelet count</p><p>Inflammation of the lining of the large bowel, caused by reduced blood supply (ischaemic colitis)</p><p>Low haemoglobin level (anaemia), low white blood cells and low platelet count will be detected by a blood test.</p><p>Thrombotic microangiopathy: clots forming in small blood vessels</p><p>&nbsp;</p><p><strong>Not known: frequency cannot be estimated from the available data </strong></p><p>Sepsis: when bacteria and their toxins circulate in the blood and starts to damage the organs</p><p>Pseudocellulitis: Skin redness with swelling</p><p>&nbsp;</p><p>You might have any of these symptoms and/or conditions. You must tell your doctor as soon as possible when you start experiencing any of these side effects.</p><p>If you are concerned about any side effects, talk to your doctor.</p><p>&nbsp;</p><p><strong>Reporting of side effects </strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in the leaflet.</p><p>You can also report side effects directly via the national reporting system listed in Section 6. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date (EXP) which is stated on the carton and the vial.</p><p>Unopened vial: Store below 30&deg;C.&nbsp;</p><p>Reconstituted solution: The product should be used immediately. When prepared as directed, chemical and physical in-use stability of reconstituted solutions of gemcitabine were demonstrated for 24 hours at 30&deg;C. Further dilution by a healthcare provider may be done. Solutions of reconstituted gemcitabine should not be refrigerated, as crystallisation may occur.</p><p>This medicine is for single use only; any unused solution should be discarded under the local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Gemzar contains</strong></p><p>- The active substance is gemcitabine. Each vial contains 200&nbsp;of gemcitabine (as gemcitabine hydrochloride).</p><p>- The other ingredients are mannitol (E421), sodium acetate, hydrochloric acid and sodium hydroxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Gemzar is a white to off-white powder, for solution for infusion in a vial. Each vial contains 200 mg of gemcitabine. Each pack of Gemzar contains 1 vial. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder:</p><p>Lilly France, 24 boulevard Vital Bouhot, CS 500014, 92521 Neuilly sur Seine Cedex, France</p><p>Manufacturer:</p><p>Lilly France, Zone industrielle, 2 rue du colonel Lilly, 67640 Fegersheim, France.</p><p>And, Vianex S.A. &ndash; Plant C 16th km Marathonos Avenue, Pallini Attiki. 15351 Greece</p><p>For any information about this medicinal product, please contact the local representative of the Marketing Authorization Holder:</p><p>Eli Lilly and Company- Saudi Arabia</p><p>PO Box 92120</p><p>16th Floor, Building Number 3074,</p><p>Tower B, Olaya Towers</p><p>Prince Mohamed Ibn Abdulaziz Street</p><p>Olaya, Riyadh</p><p>Kingdom of Saudi Arabia</p><p>Direct Line:&nbsp; +966 11 461 7800, +966 11 4617850&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Fax: +966 11 217 9900</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                February 2022 
Version 5

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي جمزار إلى مجموعة من الأدوية تُعرف ب: &quot;السامّة للخلايا&quot;. تقتل هذه الأدوية الخلايا في طور الإنقسام، بما فيها الخلايا السرطانية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن إعطاء جمزار وحده أو إلى جانب غيره من الأدوية المضادة للسرطان، تبعًا لنوع السرطان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ويُستخدم جمزار في علاج الأنواع التالية من السرطان:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الرئة ذو الخلايا غير الصغيرة (NSCLC)، وحده أو مع السيسبلاتين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان البنكرياس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الثدي، مع الباكليتاكسيل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان المَبيض، مع الكاربوبلاتين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا ينبغي استخدام جمزار</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان المريض يعاني من الحساسية (أو الحساسية المفرطة) تجاه الجيمسيتابين أو أيّ من المكوّنات الأخرى لهذا الدواء (الواردة في الفقرة 6). &nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت المريضة مُرضعة. &nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">قبل إعطائك الدواء للمرة الأولى، سيجري أخذ عينات من دمك للتأكّد من كفاءة وظائف الكبد والكليتين بما يسمح لك بتلقّي هذا الدواء. وقبل تلقّيك الدواء في كلّ مرة، ستؤخذ عيّنات من دمك للتأكّد من أنّ عدد خلايا الدّم كافٍ لتلقّي جمزار. قد يقرّر الطبيب تغيير الجرعة أو تأخير العلاج بحسب حالتك العامّة وإذا كانت خلايا دمك منخفضة جدًا. كما سيجري فحص عيّنات من دمك على نحو دوريّ للتحقّق من وظائف الكبد والكليتين. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">تحدّث إلى الطبيب أو الممرّض أو صيدلاني المستشفى قبل استخدام جمزار.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تعاني، أو سبق لك أن عانيت، من أمراض في الكبد أو القلب أو الأوعية الدموية، أو من مشاكل في الكليتين، تحدّث إلى الطبيب أو إلى صيدلاني المستشفى عن ذلك، إذ قد لا تكون قادرًا على تلقّي جمزار.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت قد خضعت في الفترة الأخيرة أو إذا كنت ستخضع قريبًا لعلاج بالأشعة، يُرجى منك إطلاع طبيبك على ذلك إذ يمكن أن يحدث تفاعل مبكر أو متأخر مع العلاج بالأشعة عند استخدام جمزار.&nbsp;&nbsp; &nbsp;&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت قد تلقّيت لقاحًا في الفترة الأخيرة، يرجى إبلاغ الطبيب، إذ يمكن أن يكون لذلك تأثيرات سلبية عند استخدام جمزار.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا عانيت أثناء العلاج بهذا الدواء من أعراض كالصداع والارتباك، أو النوبات، أو أي تغيّر في الرؤية، عليك الاتصال بالطبيب على الفور. قد يكون ذلك ناجمًا عن متلازمة اعتلال الدماغ الخلفي العكوس، وهي من الآثار الجانبيّة النادرة للغاية التي تصيب الجهاز العصبي. &nbsp;&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا عانيت من صعوبة في التنفّس أو شعرت بضعف شديد وكنت شاحبًا جدًا، عليك إطلاع طبيبك بما أنّ ذلك قد يكون من علامات الفشل الكلوي أو مشاكل الرئتين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وإذا عانيت من تورّم عام، أو ضيق في التنفّس، أو زيادة في الوزن، يُرجى منك إطلاع الطبيب بما أنّ ذلك قد يكون علامة على تسرب السوائل من الأوعية الدموية الصغيرة إلى الأنسجة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا يوصى باستخدام هذا الدواء لدى الأطفال دون سنّ 18 عامًا، نظرًا لعدم كفاية المعلومات المتعلقة بسلامته وفعاليته.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وجمزار</strong></p><p dir="RTL">أخبر طبيبك أو صيدلي المستشفى إذا كنت تتناول حاليًا أو تناولت مؤخرًا أو قد تتناول أيّ أدوية أخرى، بما في ذلك اللقاحات والأدوية التي حصلت عليها بدون وصفة طبيّة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة والخصوبة</strong></p><p dir="RTL"><strong>الحمل</strong></p><p dir="RTL">إذا كنتِ حاملًا أو تخططين للإنجاب، أخبري الطبيب، إذ ينبغي تجنّب استخدام جمزار أثناء فترة الحمل. سيناقش معك الطبيب المخاطر المحتملة للعلاج بجمزار خلال فترة الحمل.&nbsp;يجب على النساء في سن الإنجاب استخدام وسيلة منع حمل فعّالة أثناء العلاج بدواء جيمزار ولمدة 6 أشهر بعد تلقي الجرعة الأخيرة منه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإرضاع</strong></p><p dir="RTL">إذا كنتِ مرضعة، أطلعي طبيبك على ذلك.</p><p dir="RTL">عليك التوقّف عن الإرضاع خلال العلاج بجمزار.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الخصوبة</strong></p><p dir="RTL">يُنصح الرجال بالامتناع عن الإنجاب لمدة <strong>3</strong> أشهر بعد العلاج بجمزار و خلاله ولذلك يجب عليهم استخدام وسيلة منع حمل فعّالة أثناء العلاج بجيمزار ولمدّة تصل إلى 3 أشهر بعد ذلك. إذا كنتَ ترغب في إنجاب طفل خلال فترة العلاج أو خلال الأشهر الثلاثة التالية لتلقّي العلاج، استشر الطبيب أو الصيدلاني. كما يُستحسن طلب المشورة بشأن تخزين الحيوانات المنوية قبل البدء بالعلاج. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL"><strong>القيادة وتشغيل الآلات</strong></p><p dir="RTL">قد يجعلك جمزار تشعر بالنعاس، خصوصًا إذا كنت قد تناولت أي مشروبات كحولية. امتنع عن قيادة السيارة أو تشغيل أيّ آلات قبل التأكّد من أنّ العلاج بجمزار لم يجعلك تصاب بالنعاس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي جمزار على الصوديوم</strong></p><p dir="RTL">يحتوي جمزار على 3.5 ملجم (&lt; 1 مليمول) من الصوديوم في كلّ قارورة 200 ملجم، و 17.5 ملجم (&lt; 1 مليمول) من الصوديوم في كلّ قارورة 1000 ملجم، أي أنّه عمليًا خالٍ من الصوديوم.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الجرعة المعتادة من جمزار هي 1000-1250 ملجم لكلّ متر مربّع من مساحة سطح الجسم. يجري قياس طولك ووزنك لاحتساب مساحة سطح جسمك. ويستند الطبيب إلى هذه المساحة لاحتساب الجرعة المناسبة لك. وقد يتمّ تعديل هذه الجرعة أو تأخير العلاج بحسب عدد خلايا دمك وحالتك العامّة. &nbsp;&nbsp;&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">أمّا وتيرة تلقّيك للعلاج بجمزار فتعتمد على نوع السرطان الذي تُعالَج منه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيقوم صيدليّ المستشفى أو الطبيب بإذابة بودرة جمزار قبل إعطائه لك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ستتلقّى جمزار في كلّ مرة عن طريق التسريب الوريدي الذي يستمرّ لمدة 30 دقيقة تقريبًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة أخرى حول استخدام هذا الدواء، يرجى منك توجيهها إلى الطبيب أو الصيدلاني.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">على غرار جميع الأدوية، قد يسبّب جمزار آثارًا جانبية، إنما لا تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>عليك الاتصال بطبيبك مباشرة إذا لاحظت أيًا من الأعراض التالية: </strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف من اللثة أو الأنف أو الفم، أو أي نزيف لا يتوقف، أو تغيّر لون البول إلى الأحمر أو الوردي، أو ظهور كدمات غير متوقعة (نظرًا لإمكانيةّ انخفاض تعداد الصفيحات الدموية عن مستواها الاعتيادي، وهو أمرٌ شائع جدًا).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعب، والشعور بالوهن، وسرعة الإصابة باللهاث، والشحوب (نظرًا لإمكانيةّ انخفاض مستوى خضاب الدم (الهيموغلوبين) عن معدّله الاعتيادي، وهو أمرٌ شائع جدًا).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلديّ طفيف إلى متوسّط (شائع جدًا) / &nbsp;حكّة (شائعة)، أو حمّى (شائعة جدًا)، (تفاعلات تحسسية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; درجة حرارة الجسم 38 مئوية أو أكثر، تعرّق أو غيرها من علامات العدوى (إذ قد تكون خلايا الدم البيضاء لديك أقلّ من المعتاد، ومصحوبة بالحمّى أو ما يُعرف باسم قلة العدلات الحموية) (أثر شائع). &nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم، احمرار، تورّم أو تقرّحات في الفم (التهاب الفم) (شائع).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم انتظام ضربات القلب (اضطراب النبض) (غير شائع)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعب والوهن الشديدان، الفرفرية أو النزف في مساحات صغيرة من الجلد (الكدمات)، الفشل الكلوي الحاد (انخفاض كمية البول أو انعدام التبوّل)، وعلامات العدوى (متلازمة انحلال الدم اليوريمي). قد تكون مميتة (غير شائعة).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفّس (من الشائع الشعور بصعوبة طفيفة في التنفّس بُعيد تلقّي دواء جمزار، إلّا أنّ ذلك لا يستمر طويلًا، لكن في حالات قليلة أو نادرة قد يتعرّض المريض لمشاكل رئوية أكثر حدّة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألمٌ حادٌ في الصدر (احتشاء عضل القلب) (نادر)<strong>.</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط حساسية شديد/ردّ فعل تحسسي مع طفح جلدي حاد يشمل الإحمرار والحكة الجلدية، تورّم اليدين، أو القدمين، أو الكاحلين، أو الوجه، أو الشفتين، أو الفم، أو الحلق (ما قد يسبّب صعوبة في البلع أو التنفّس)، وأزيز عند التنفّس، وسرعة خفقان القلب، كما قد تشعر بأنّه سيُغمى عليك (تفاعل تأقي) (نادر جدًا).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورّم عام، أو ضيق في التنفّس، أو زيادة في الوزن، إذ إنّك قد تعاني من تسرب السوائل من الأوعية الدموية الصغيرة إلى الأنسجة (متلازمة التسرّب الشعيري) (نادر جدًا)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع المصحوب بتغيّرات في الرؤية وارتباك أو نوبات (متلازمة اعتلال الدماغ الخلفي العكوس) (نادرة جدًا)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي حاد مصحوب بالحكة أو التنفّط أو تقشّر الجلد (متلازمة ستيفنز جونسون، تقشر الأنسجة المتموتة البشروية التسممي) (نادرة جدًا).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعب الشديد والضعف، كدمات أو مناطق نزيف صغيرة في الجلد، والفشل الكلوي الحاد (انخفاض إنتاج البول أو عدم إخراج البول)، وعلامات العدوى. قد تكون هذه من مظاهر اعتلال الأوعية الدقيقة الخثاري (جلطات تتكوّن في أوعية دموية صغيرة) ومتلازمة الإلتهاب الوريدي الانحلالي، والذي قد يكون قاتلاً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>وتشمل الآثار الجانبية الأخرى لجمزار: </strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>آثار جانبية شائعة جدًا </strong>(قد تصيب أكثر من 1 من بين كلّ 10 أشخاص)</p><p dir="RTL">انخفاض تعداد خلايا الدّم البيضاء</p><p dir="RTL">صعوبة في التنفّس</p><p dir="RTL">تقيؤ</p><p dir="RTL">غثيان</p><p dir="RTL">تساقط الشعر</p><p dir="RTL">مشاكل في الكبد: تظهر من خلال نتائج تحاليل الدم غير الطبيعية</p><p dir="RTL">الدّم في البول</p><p dir="RTL">نتائج تحليل البول غير الطبيعية: البروتينات في البول</p><p dir="RTL">الأعراض المشابهة لأعراض الانفلونزا</p><p dir="RTL">تورّم الكاحلين والأصابع والقدمين والوجه (وذمة)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية شائعة </strong>(قد تصيب 1 من بين كلّ 10 أشخاص)</p><p dir="RTL">ضعف الشهية (فقدُ الشهيّة)</p><p dir="RTL">الصداع</p><p dir="RTL">الأرق</p><p dir="RTL">النُّعاس</p><p dir="RTL">السّعال</p><p dir="RTL">سيلان الأنف</p><p dir="RTL">الإمساك</p><p dir="RTL">الإسهال</p><p dir="RTL">الحكّة</p><p dir="RTL">التعرّق</p><p dir="RTL">الآلام العضلية</p><p dir="RTL">ألم الظهر</p><p dir="RTL">الحمّى</p><p dir="RTL">الوهن</p><p dir="RTL">القشعريرة</p><p dir="RTL">العدوى</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية غير شائعة </strong>(قد تصيب 1 من بين كلّ 100 شخص)</p><p dir="RTL">تندّب الأكياس الهوائية الرئوية (الإلتهاب الرئوي الخلاليّ)</p><p dir="RTL">الصفير عند التنفّس (تشنّج الشعب الهوائية)</p><p dir="RTL">تندّب الرئتين (صور الأشعة للصدر تظهر/التصوير المقطعي للصدر يظهر نتائج غير طبيعية)</p><p dir="RTL">فشل القلب</p><p dir="RTL">الفشل الكلوي</p><p dir="RTL">ضرر جسيم في الكبد، بما في ذلك قصور الكبد</p><p dir="RTL">السكتة الدماغية&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية نادرة </strong>(قد تصيب 1 من بين كلّ 1000 شخص)</p><p dir="RTL">انخفاض ضغط الدّم</p><p dir="RTL">تقشّر الجلد، التقرّح أو تشكّل النفطات</p><p dir="RTL">انسلاخ الجلد والتقرّحات الجلدية الشديدة</p><p dir="RTL">التفاعلات في موضع الحقن</p><p dir="RTL">التهاب رئوي حاد يؤدّي إلى فشل تنفّسي (متلازمة الضائقة التنفسية لدى البالغين)</p><p dir="RTL">طفح جلدي يشبه الحرق الشمسي الشديد، قد يصيب الجلد الذي سبق له التعرّض للعلاج بالأشعة (ظاهرة المعاودة الإشعاعية).</p><p dir="RTL">سائل في الرئتين</p><p dir="RTL">تندّب الأكياس الهوائية الرئوية الناجم عن العلاج بالأشعة (التسمّم الإشعاعي) &nbsp;&nbsp;</p><p dir="RTL">غرغرينا الأصابع أو أصابع القدم</p><p dir="RTL">التهاب الأوعية الدموية (الإلتهاب الوعائي الطرفي)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية نادرة جدًا </strong>(قد تصيب 1 من بين كلّ 10000 شخص)</p><p dir="RTL">ارتفاع تعداد الصفيحات الدموية</p><p dir="RTL">التهاب بطانة الأمعاء الغليظة، بسبب انخفاض التدفق الدموي (التهاب القولون الإقفاري)</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">انخفاض مستوى خضاب الدم (فقر الدّم)، انخفاض تعداد خلايا الدّم البيضاء، وانخفاض تعداد الصفيحات الدموية في تحاليل الدمّ.&nbsp;&nbsp; &nbsp;&nbsp;</p><p dir="RTL">اعتلال الأوعية الدموية الخثاري: جلطات تتشكل في الأوعية الدموية الصغيرة</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>غير معروف: لا يمكن تقدير التردد من خلال البيانات المتاحة</strong></p><p dir="RTL">تعفن الدم: عندما تنتشر البكتيريا وسمومها في الدم وتبدأ في تلف الأعضاء</p><p dir="RTL">التهاب كاذبة: احمرار الجلد مع تورم</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تصاب بأيّ من هذه الأعراض و/أو الحالات المرضيّة. عليك إبلاغ طبيبك بأسرع وقت ممكن عندما تشعر بأيّ من هذه الآثار الجانبيّة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت قلقًا بشأن أيّ من الآثار الجانبية، تحدّث مع طبيبك.</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا شعرت بأيّ آثار جانبية، تحدّث مع الطبيب أو الصيدلي. ويشمل هذا أيّ آثار جانبية محتملة غير مدرجة في هذه النشرة.</p><p dir="RTL">كما يمكنك الإبلاغ عن الآثار الجانبية مباشرة عبر نظام الإبلاغ الوطني المذكور في &nbsp;المقطع 6. من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساهمة في توفير مزيد من المعلومات حول سلامة هذا الدواء. &nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا الدواء بعيدًا عن مرأى الأطفال ومتناولهم.</p><p dir="RTL">ينبغي الامتناع عن استخدام هذا الدواء بعد تاريخ انتهاء صلاحيته (EXP) المحدّد على العلبة وعلى القارورة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">القارورة غير المفتوحة: تخزن في درجة حرارة أقل من<strong> </strong>30<strong> </strong>درجة مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">المحلول المعاد تشكيله: ينبغي استعماله على الفور. لقد أُثبت الثبات الكيميائي والفيزيائي لمحلول الجيمسيتابين المذاب لمدّة 24 ساعة في حرارة 30<strong> </strong>درجة &nbsp;مئوية، في حال إعداده وفقًا للإرشادات المحددة، ويمكن لأحد مقدّمي الرعاية الصحية أن يقوم بتخفيف المحلول أكثر. ينبغي الامتناع عن تبريد محلول الجيمسيتابين نظرًا لإمكانية حدوث التبلور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">هذا الدواء معدّ للاستخدام مرّة واحدة فقط؛ وينبغي التخلّص من أي كمية غير مستعملة من المحلول وفقًا للمتطلبات المحلية.&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما يحتويه جمزار </strong></p><p dir="RTL">- المادة الفعّالة في هذا الدواء هي الجيمسيتابين. تحتوي كلّ قارورة على 200 ملجم من الجيمسيتابين (على شكل هيدروكلوريد الجيمسيتابين).</p><p dir="RTL">- المكونات الأخرى هي: المانيتول (E421)، أسيتات الصوديوم، حمض الهيدروكلوريك، هيدروكسيد الصوديوم. &nbsp;&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">جمزار عبارة عن مسحوق أبيض أو أبيض مائل إلى الصفرة داخل قارورة، مخصص لتحضير محلول للتسريب الوريدي. تحتوي كلّ قارورة على 200 ملجم من الجيمسيتابين، وتحتوي كلّ عبوة من جمزار على قارورة واحدة.&nbsp;&nbsp; &nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">حامل ترخيص التسويق:</p><p dir="RTL">&nbsp;لیلي فرنسا،24 &nbsp;بوليفاردفیتال بوھو،CS 50004 ، 92521 نویي &nbsp;سورسین سیدیكس، فرنسا.</p><p dir="RTL">المصنّع:</p><p dir="RTL">ليلي فرنسا، المنطقة الصناعية، &nbsp;2طريق الكلونيل ليلي، فغرشايم، فرنسا.</p><p dir="RTL">وڤيانكس&nbsp; &nbsp;- S.A.مصنع سي،16 &nbsp;كلم طريق مراتونوس أفينيو، باليني عتيقي. &nbsp;15351اليونان.</p><p dir="RTL">للحصول على أي معلومات عن هذا الدواء، يُرجى الاتصال بالممثل المحلي<strong> </strong>للشركة صاحبة تفويض التسويق<strong>:</strong></p><p dir="RTL">شركة إيلي ليلي آند كومباني &ndash; المملكة العربية السعودية</p><p dir="RTL">ص.ب: 92120</p><p dir="RTL">الطابق 16، مبنى رقم 3074،</p><p dir="RTL">برج ب، أبراج العُليَّا</p><p dir="RTL">شارع الأمير محمد بن عبد العزيز</p><p dir="RTL">العُليَّا، الرياض</p><p dir="RTL">المملكة العربية السعودية</p><p dir="RTL">الخط المباشر: 966114617800<strong>+</strong>، +966114617850</p><p dir="RTL">الفاكس: 966112179900<strong>+</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            فبراير 2022 
النسخة ٥
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gemzar 200 mg powder for solution for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One vial contains gemcitabine hydrochloride equivalent to 200 mg gemcitabine.
After reconstitution, the solution contains 38 mg/ml of gemcitabine. 
Excipients
Each 200 mg vial contains 3.5 mg (<1 mmol) sodium.
For a full list of excipients see section 6.1.  
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for solution for infusion. 
White to off-white plug or powder.
Vials containing sterile lyophilized gemcitabine hydrochloride equivalent to 200 mg gemcitabine for intravenous use.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas.</p><p>Gemcitabine, in combination with cisplatin is indicated as first line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). Gemcitabine monotherapy can be considered in elderly patients or those with performance status 2.</p><p>Gemcitabine is indicated for the treatment of patients with locally advanced or metastatic epithelial ovarian carcinoma, in combination with carboplatin, in patients with relapsed disease following a recurrence-free interval of at least 6 months after platinum-based, first-line therapy.</p><p>Gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>GEMZAR is a hazardous drug. Follow applicable special handling and disposal procedures in section 6.6.</p><p>Gemcitabine should only be prescribed by a physician qualified in the use of anti-cancer chemotherapy.</p><p><u>Posology</u></p><p><em><u>Pancreatic cancer </u></em></p><p>The recommended dose of gemcitabine is 1000&nbsp;mg/m<sup>2</sup>, given by 30‑minute intravenous infusion. This should be repeated once weekly for up to 7 weeks followed by a week of rest. Subsequent cycles should consist of injections once weekly for 3 consecutive weeks out of every 4 weeks. Dosage reduction with each cycle or within a cycle may be applied based upon the grade of toxicity experienced by the patient.</p><p><em><u>Non small Cell lung cancer</u></em></p><p><em>Monotherapy</em></p><p>The recommended dose of gemcitabine is 1000&nbsp;mg/m<sup>2</sup>, given by 30‑minute intravenous infusion. This should be repeated once weekly for 3 weeks, followed by a 1‑week rest period. This 4‑week cycle is then repeated. Dosage reduction with each cycle or within a cycle may be applied based upon the grade of toxicity experienced by the patient.</p><p><em>Combination use</em></p><p>The recommended dose for gemcitabine is 1250&nbsp;mg/m<sup>2</sup> body surface area given as a 30‑minute intravenous infusion on Day 1 and 8 of the treatment cycle (21 days). Dosage reduction with each cycle or within a cycle may be applied based upon the grade of toxicity experienced by the patient.</p><p>Cisplatin has been used at doses between 75-100&nbsp;mg/m<sup>2 </sup>once every 3 weeks.</p><p><em><u>Breast cancer</u></em></p><p><em>Combination use</em></p><p>Gemcitabine in combination with paclitaxel is recommended using paclitaxel (175&nbsp;mg/m<sup>2</sup>) administered on Day 1 over approximately 3‑hours as an intravenous infusion, followed by gemcitabine (1250&nbsp;mg/m<sup>2</sup>) as a 30‑minute intravenous infusion on Days 1 and 8 of each 21‑day cycle.&nbsp; Dose reduction with each cycle or within a cycle may be applied based upon the grade of toxicity experienced by the patient. Patients should have an absolute granulocyte count of at least 1,500&nbsp;(x 10<sup>6</sup>/l) prior to initiation of gemcitabine + paclitaxel combination.</p><p><em><u>Ovarian cancer</u></em></p><p><em>Combination use</em></p><p>Gemcitabine in combination with carboplatin is recommended using gemcitabine 1000&nbsp;mg/m<sup>2</sup> administered on Days 1 and 8 of each 21‑day cycle as a 30‑minute intravenous infusion. After gemcitabine, carboplatin will be given on Day 1 consistent with a target Area under curve (AUC) of 4.0&nbsp;mg/ml∙min. Dosage reduction with each cycle or within a cycle may be applied based upon the grade of toxicity experienced by the patient.</p><p><u>Monitoring for toxicity and dose modification due to toxicity</u></p><p><em><u>Dose modification due to non haematological toxicity</u></em></p><p>Periodic physical examination and checks of renal and hepatic function should be made to detect non-haematological toxicity. Dosage reduction with each cycle or within a cycle may be applied based upon the grade of toxicity experienced by the patient. In general, for severe (Grade 3 or 4) non-haematological toxicity, except nausea/vomiting, therapy with gemcitabine should be withheld or decreased depending on the judgement of the treating physician. Doses should be withheld until toxicity has resolved in the opinion of the physician.</p><p>For cisplatin, carboplatin, and paclitaxel dosage adjustment in combination therapy, please refer to the corresponding Summary of Product Characteristics.</p><p><em><u>Dose modification due to haematological toxicity</u></em></p><p><em>Initiation of a cycle</em></p><p>For all indications, the patient must be monitored before each dose for platelet and granulocyte counts. Patients should have an absolute granulocyte count of at least 1,500 (x 10<sup>6</sup>/l) and platelet count of 100,000 (x 10<sup>6</sup>/l) prior to the initiation of a cycle.&nbsp;</p><p><em>Within a cycle</em></p><p>Dose modifications of gemcitabine within a cycle should be performed according to the following tables:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Dose modification of gemcitabine within a cycle for NSCLC and pancreatic cancer, given in monotherapy or in combination with cisplatin</strong></p></td></tr><tr><td style="vertical-align:top"><p>Absolute granulocyte count</p><p>(x 10<sup>6</sup>/l)</p></td><td style="vertical-align:top"><p><strong>Platelet count </strong></p><p><strong>(x 10<sup>6</sup>/l)</strong></p></td><td style="vertical-align:top"><p><strong>Percentage of standard dose of Gemzar (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&gt; 1,000&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&gt; 100,000</p></td><td style="vertical-align:top"><p>100</p></td></tr><tr><td style="vertical-align:top"><p>500-1,000&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; or&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>50,000-100,000</p></td><td style="vertical-align:top"><p>75&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&lt;500 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&lt; 50,000</p></td><td style="vertical-align:top"><p>Omit dose *</p></td></tr></tbody></table><p>*Treatment omitted will not be re-instated within a cycle before the absolute granulocyte count reaches at least 500 (x10<sup>6</sup>/l) and the platelet count reaches 50,000 (x10<sup>6</sup>/l). &nbsp;</p><p><u>&nbsp;</u></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Dose modification of gemcitabine within a cycle for breast cancer, given in combination with paclitaxel</strong></p></td></tr><tr><td style="vertical-align:top"><p>Absolute granulocyte count</p><p>(x 10<sup>6</sup>/l)</p></td><td style="vertical-align:top"><p><strong>Platelet count </strong></p><p><strong>(x 10<sup>6</sup>/l)</strong></p></td><td style="vertical-align:top"><p><strong>Percentage of standard dose of Gemzar (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&ge; 1,200&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&gt;75,000</p></td><td style="vertical-align:top"><p>100</p></td></tr><tr><td style="vertical-align:top"><p>1,000- &lt;1,200&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;or</p></td><td style="vertical-align:top"><p>50,000-75,000</p></td><td style="vertical-align:top"><p>75</p></td></tr><tr><td style="vertical-align:top"><p>700- &lt;1,000&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;and</p></td><td style="vertical-align:top"><p>&ge; 50,000</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p>&lt;700&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;or</p></td><td style="vertical-align:top"><p>&lt;50,000</p></td><td style="vertical-align:top"><p>Omit dose*</p></td></tr></tbody></table><p>*Treatment omitted will not be re-instated within a cycle.&nbsp; Treatment will start on day 1 of the next cycle once the absolute granulocyte count reaches at least 1,500 (x10<sup>6</sup>/l) and the platelet count reaches 100,000 (x10<sup>6</sup>/l).</p><p><u>&nbsp;</u></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Dose modification of gemcitabine within a cycle for ovarian cancer, given in combination with carboplatin</strong></p></td></tr><tr><td style="vertical-align:top"><p>Absolute granulocyte count</p><p>(x 10<sup>6</sup>/l)</p></td><td style="vertical-align:top"><p><strong>Platelet count </strong></p><p><strong>(x 10<sup>6</sup>/l)</strong></p></td><td style="vertical-align:top"><p><strong>Percentage of standard dose of Gemzar (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&gt; 1,500&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&ge; 100,000</p></td><td style="vertical-align:top"><p>100</p></td></tr><tr><td style="vertical-align:top"><p>1000-1,500&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>75,000-100,000</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p>&lt;1000&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&lt; 75,000</p></td><td style="vertical-align:top"><p>Omit dose*</p></td></tr></tbody></table><p>*Treatment omitted will not be re-instated within a cycle.&nbsp; Treatment will start on day 1 of the next cycle once the absolute granulocyte count reaches at least 1,500 (x10<sup>6</sup>/l) and the platelet count reaches 100,000 (x10<sup>6</sup>/l).</p><p>&nbsp;</p><p><em>Dose modifications due to haematological toxicity in subsequent cycles, for all indications</em></p><p>The gemcitabine dose should be reduced to 75% of the original cycle initiation dose, in the case of the following haematological toxicities:</p><ul><li>Absolute granulocyte count &lt; 500 x 10<sup>6</sup>/l<strong> </strong>for more than 5 days</li><li>Absolute granulocyte count &lt; 100 x 10<sup>6</sup>/l<strong> </strong>for more than 3 days</li><li>Febrile neutropaenia</li><li>Platelets &lt; 25,000 x 10<sup>6</sup>/l</li><li>Cycle delay of more than 1 week due to toxicity</li></ul><p><u>Method of administration</u></p><p>Gemzar is tolerated well during infusion and may be administered ambulant. If extravasation occurs, generally the infusion must be stopped immediately and started again in another blood vessel. The patient should be monitored carefully after the administration.</p><p>For instructions on reconstitution, see section 6.6</p><p><u>Special populations</u></p><p><em><u>Patients with renal or hepatic impairmen</u></em><em>t</em></p><p>Gemcitabine should be used with caution in patients with hepatic or renal impairment as there is insufficient information from clinical studies to allow for clear dose recommendations for these patient populations (see sections 4.4 and 5.2).</p><p><em><u>Older people (&gt; 65 years)</u></em></p><p>Gemcitabine has been well tolerated in patients over the age of 65. There is no evidence to suggest that dose adjustments, other than those already recommended for all patients, are necessary in older people (see section 5.2).</p><p><em><u>Paediatric population (&lt; 18 years)</u></em></p><p>Gemcitabine is not recommended for use in children under 18 years of age due to insufficient data on safety and efficacy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients. 
Breast-feeding (see section 4.6).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Prolongation of the infusion time and increased dosing frequency have been shown to increase toxicity.</p><p><u>Haematological toxicity</u></p><p>Gemcitabine can suppress bone marrow function as manifested by leucopaenia, thrombocytopaenia and anaemia.</p><p>Patients receiving gemcitabine should be monitored prior to each dose for platelet, leucocyte and granulocyte counts. Suspension or modification of therapy should be considered when drug-induced bone marrow depression is detected (see section 4.2). However, myelosuppression is short lived and usually does not result in dose reduction and rarely in discontinuation.</p><p>Peripheral blood counts may continue to deteriorate after gemcitabine administration has been stopped. In patients with impaired bone marrow function, the treatment should be started with caution. As with other cytotoxic treatments, the risk of cumulative bone-marrow suppression must be considered when gemcitabine treatment is given together with other chemotherapy.</p><p><u>Hepatic and renal impairment</u></p><p>Gemcitabine should be used with caution in patients with hepatic or renal function impairment as there is insufficient information from clinical studies to allow clear dose recommendation for this patient population (see section 4.2).</p><p>Administration of gemcitabine in patients with concurrent liver metastases or a pre-existing medical history of hepatitis, alcoholism or liver cirrhosis may lead to exacerbation of the underlying hepatic impairment.</p><p>Laboratory evaluation of renal and hepatic function (including virological tests) should be performed periodically.</p><p><u>Concomitant radiotherapy</u></p><p>Concomitant radiotherapy (given together or &pound;7 days apart): Toxicity has been reported (see section 4.5 for details and recommendations for use).</p><p><u>Live vaccinations</u></p><p>Yellow fever vaccine and other live attenuated vaccines are not recommended in patients treated with gemcitabine (see section 4.5).</p><p><u>Posterior reversible encephalopathy syndrome</u></p><p>Reports of posterior reversible encephalopathy syndrome (PRES) with potentially severe consequences have been reported in patients receiving gemcitabine as single agent or in combination with other chemotherapeutic agents. Acute hypertension and seizure activity were reported in most gemcitabine patients experiencing PRES, but other symptoms such as headache, lethargy, confusion and blindness could also be present. Diagnosis is optimally confirmed by magnetic resonance imaging (MRI). PRES was typically reversible with appropriate supportive measures. Gemcitabine should be permanently discontinued and supportive measures implemented, including blood pressure control and anti-seizure therapy, if PRES develops during therapy.</p><p><u>Cardiovascular</u></p><p>Due to the risk of cardiac and/or vascular disorders with gemcitabine, particular caution must be exercised with patients presenting a history of cardiovascular events.</p><p><em>Capillary leak syndrome</em></p><p>Capillary leak syndrome has been reported in patients receiving gemcitabine as single agent or in combination with other chemotherapeutic agents (see section 4.8). The condition is usually treatable if recognised early and managed appropriately, but fatal cases have been reported. The condition involves systemic capillary hyperpermeability during which fluid and proteins from the intravascular space leak into the interstitium. The clinical features include generalised oedema, weight gain, hypoalbuminaemia, severe hypotension, acute renal impairment and pulmonary oedema.&nbsp; Gemcitabine should be discontinued and supportive measures implemented if capillary leak syndrome develops during therapy. Capillary leak syndrome can occur in later cycles and has been associated in the literature with adult respiratory distress syndrome.</p><p><u>Pulmonary</u></p><p>Pulmonary effects, sometimes severe (such as pulmonary oedema, interstitial pneumonitis or adult respiratory distress syndrome (ARDS)) have been reported in association with gemcitabine therapy. If such effects develop, consideration should be made to discontinuing gemcitabine therapy. Early use of supportive care measure may help ameliorate the condition.</p><p><u>Renal</u></p><p><em>Haemolytic uraemic syndrome</em></p><p>Clinical findings consistent with the haemolytic uraemic syndrome (HUS) were rarely reported (post- marketing data) in patients receiving gemcitabine (see section 4.8). HUS is a potentially life-threatening disorder. Gemcitabine should be discontinued at the first signs of any evidence of microangiopathic haemolytic anaemia, such as rapidly falling haemoglobin with concomitant thrombocytopaenia, elevation of serum bilirubin, serum creatinine, blood urea nitrogen, or LDH. Renal failure may not be reversible with discontinuation of therapy and dialysis may be required.</p><p><u>Fertility</u></p><p>In fertility studies gemcitabine caused hypospermatogenesis in male mice (see section 5.3). Therefore, men being treated with gemcitabine are advised not to father a child during and up to 3 months after treatment and to seek further advice regarding cryoconservation of sperm prior to treatment because of the possibility of infertility due to therapy with gemcitabine (see section 4.6).</p><p>&nbsp;</p><p><u>Sodium</u></p><p>Gemzar 200&nbsp;mg contains 3.5&nbsp;mg (&lt;1 mmol) sodium per vial ie essentially sodium free. &nbsp;</p><p>&nbsp;</p><p>Gemzar 1000&nbsp;mg contains 17.5&nbsp;mg (&lt; 1 mmol) sodium per vial ie essentially sodium free.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific interaction studies have been performed (see section 5.2)</p><p>&nbsp;</p><p><u>Radiotherapy</u></p><p>Concurrent (given together or &pound;&nbsp;7 days apart) - Toxicity associated with this multimodality therapy is dependent on many different factors, including dose of gemcitabine, frequency of gemcitabine administration, dose of radiation, radiotherapy planning technique, the target tissue, and target volume. &nbsp;Pre-clinical and clinical studies have shown that gemcitabine has radiosensitising activity. In a single trial, where gemcitabine at a dose of 1,000&nbsp;mg/m<sup>2</sup> was administered concurrently for up to 6 consecutive weeks with therapeutic thoracic radiation to patients with non-small cell lung cancer, significant toxicity in the form of severe, and potentially life threatening mucositis, especially oesophagitis, and pneumonitis was observed, particularly in patients receiving large volumes of radiotherapy [median treatment volumes 4,795&nbsp;cm<sup>3</sup>]. Studies done subsequently have suggested that it is feasible to administer gemcitabine at lower doses with concurrent radiotherapy with predictable toxicity, such as a phase II study in non-small cell lung cancer, where thoracic radiation doses of 66&nbsp;Gy were applied concomitantly with an administration with gemcitabine (600&nbsp;mg/m<sup>2</sup>, four times) and cisplatin (80&nbsp;mg/m<sup>2 </sup>twice) during 6 weeks. The optimum regimen for safe administration of gemcitabine with therapeutic doses of radiation has not yet been determined in all tumour types.</p><p>&nbsp;</p><p>Non-concurrent (given &gt;7&nbsp;days apart)- Analysis of the data does not indicate any enhanced toxicity when gemcitabine is administered more than 7 days before or after radiation, other than radiation recall. Data suggest that gemcitabine can be started after the acute effects of radiation have resolved or at least one week after radiation. &nbsp;</p><p>&nbsp;</p><p>Radiation injury has been reported on targeted tissues (e.g. oesophagitis, colitis, and pneumonitis) in association with both concurrent and non-concurrent use of gemcitabine. &nbsp;</p><p>&nbsp;</p><p><u>Others</u></p><p>Yellow fever and other live attenuated vaccines are not recommended due to the risk of systemic, possibly fatal, disease, particularly in immunosuppressed patients.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential/contraception in men and women</u></p><p>Due to the genotoxic potential of gemcitabine (see section 5.3), women of childbearing potential should use effective contraceptive measures while being treated with gemcitabine and for 6 months following completion of treatment.</p><p>Men are recommended to use effective contraceptive measures and to not father a child while receiving gemcitabine and for 3 months following completion of treatment.</p><p><u>Pregnancy</u></p><p>There are no adequate data from the use of gemcitabine in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). Based on results from animal studies and the mechanism of action of gemcitabine, this substance should not be used during pregnancy unless clearly necessary. Women should be advised not to become pregnant during treatment with gemcitabine and to warn their attending physician immediately, should this occur after all.</p><p><u>Breast-feeding</u></p><p>It is not known whether gemcitabine is excreted in human milk and adverse effects on the suckling child cannot be excluded. Breast-feeding must be discontinued during gemcitabine therapy.</p><p><u>Fertility</u></p><p>In fertility studies gemcitabine caused hypospermatogenesis in male mice (see section 5.3). Therefore, men being treated with gemcitabine are advised not to father a child during and up to 3&nbsp;months after treatment and to seek further advice regarding cryoconservation of sperm prior to treatment because of the possibility of infertility due to therapy with gemcitabine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. However, gemcitabine has been reported to cause mild to moderate somnolence, especially in combination with alcohol consumption. Patients should be cautioned against driving or operating machinery until it is established that they do not become somnolent.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most commonly reported adverse drug reactions associated with Gemzar treatment include: nausea with or without vomiting, raised liver transaminases (AST/ALT) and alkaline phosphatase, reported in approximately 60% of patients; proteinuria and haematuria reported in approximately 50% patients; dyspnoea reported in 10‑40% of patients (highest incidence in lung cancer patients); allergic skin rashes occur in approximately 25% of patients and are associated with itching in 10% of patients.</p><p>&nbsp;</p><p>The frequency and severity of the adverse reactions are affected by the dose, infusion rate and intervals between doses (see section 4.4). Dose‑limiting adverse reactions are reductions in thrombocyte, leucocyte and granulocyte counts (see section 4.2).</p><p>&nbsp;</p><p><u>Clinical trial data</u></p><p>Frequencies are defined as: Very common (&ge;1/10), Common (&sup3;1/100 to &lt;1/10), Uncommon (&ge;1/1000 to &lt;1/100), Rare (&ge;1/10,000 to &lt;1/1000), Very Rare (&lt;1/10,000).&nbsp;</p><p>&nbsp;</p><p>The following table of undesirable effects and frequencies is based on data from clinical trials. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p>System Organ Class</p></td><td style="vertical-align:top"><p>Frequency grouping</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Common</p><ul><li>Infections</li></ul><p>&nbsp;</p><p>Not known</p><ul><li>Sepsis</li></ul></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Very common</p><ul><li>Leucopaenia (Neutropaenia Grade 3 = 19.3&nbsp;%; Grade 4 = 6&nbsp;%).</li></ul><p>Bone-marrow suppression is usually mild to moderate and mostly affects the granulocyte count (see section 4.2 and 4.4)</p><ul><li>Thrombocytopaenia</li><li>Anaemia</li></ul><p>&nbsp;</p><p>Common</p><ul><li>Febrile neutropaenia</li></ul><p>&nbsp;</p><p>Very rare</p><ul><li>Thrombocytosis</li><li>Thrombotic microangiopathy</li></ul></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Very Rare</p><ul><li>Anaphylactoid reaction</li></ul></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Common</p><ul><li>Anorexia</li></ul></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Common</p><ul><li>Headache</li><li>Insomnia</li><li>Somnolence</li></ul><p>Uncommon</p><ul><li>Cerebrovascular accident</li></ul><p>Very rare</p><ul><li>Posterior reversible encephalopathy syndrome (see section 4.4.)</li></ul></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Uncommon</p><ul><li>Arrhythmias, predominantly supraventricular in nature</li><li>&nbsp; Heart failure</li></ul><p>Rare</p><ul><li>Myocardial infarct</li></ul></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Rare</p><ul><li>&nbsp; Clinical signs of peripheral vasculitis and gangrene</li></ul><ul><li>Hypotension</li></ul><p>&nbsp;</p><p>Very rare</p><ul><li>Capillary leak syndrome (see section 4.4)</li></ul></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Very common</p><ul><li>Dyspnoea &ndash;usually mild and passes rapidly without treatment</li></ul><p>&nbsp;</p><p>Common</p><ul><li>Cough</li><li>Rhinitis</li></ul><p>&nbsp;</p><p>Uncommon</p><ul><li>Interstitial pneumonitis (see section 4.4)</li><li>Bronchospasm &ndash;usually mild and transient but may require parenteral treatment</li></ul><p>&nbsp;</p><p>Rare</p><ul><li>&nbsp;&nbsp; Pulmonary oedema</li></ul><ul><li>Adult respiratory distress syndrome (see section 4.4.)</li></ul></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Very common</p><ul><li>Vomiting</li><li>Nausea</li></ul><p>&nbsp;</p><p>Common</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stomatitis and ulceration of the mouth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Constipation</p><p>&nbsp;</p><p>Very rare</p><ul><li>&nbsp; Ischaemic colitis</li></ul></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Very common</p><ul><li>Elevation of liver transaminases (AST and ALT) and alkaline phosphatase</li></ul><p>&nbsp;</p><p>Common</p><ul><li>Increased bilirubin</li></ul><p>&nbsp;</p><p>Uncommon</p><ul><li>&nbsp;&nbsp; Serious hepatotoxicity, including liver failure and death</li></ul><p>&nbsp;</p><p>Rare</p><ul><li>Increased gamma-glutamyl transferase (GGT)</li></ul></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Very common</p><ul><li>Allergic skin rash frequently associated with pruritus</li><li>Alopecia</li></ul><p>&nbsp;</p><p>Common</p><ul><li>Itching</li><li>Sweating</li></ul><p>&nbsp;</p><p>Rare</p><ul><li>&nbsp;&nbsp; Severe skin reactions, including desquamation and bullous skin eruptions</li></ul><ul><li>Ulceration</li><li>Vesicle and sore formation</li><li>Scaling</li></ul><p>&nbsp;</p><p>Very rare&nbsp;</p><ul><li>Toxic epidermal necrolysis</li><li>Stevens-Johnson Syndrome&nbsp;</li></ul><p>&nbsp;</p><p>Not known:</p><ul><li>Pseudocellulitis</li></ul></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Common</p><ul><li>Back pain</li><li>Myalgia</li></ul></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Very Common</p><ul><li>Haematuria</li><li>Mild proteinuria</li></ul><p>&nbsp;</p><p>Uncommon</p><ul><li>Renal failure (see section 4.4)</li></ul><ul><li>Haemolytic uraemic syndrome (see section 4.4)</li></ul></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Very common</p><ul><li>Influenza-like symptoms - the most common symptoms are fever, headache, chills, myalgia, asthenia and anorexia. Cough, rhinitis, malaise, perspiration and sleeping difficulties have also been reported.</li><li>Oedema/peripheral oedema-including facial oedema.&nbsp; Oedema is usually reversible after stopping treatment</li></ul><p>&nbsp;</p><p>Common</p><ul><li>Fever</li><li>Asthenia</li><li>Chills</li></ul><p>&nbsp;</p><p>Rare</p><ul><li>Injection site reactions-mainly mild in nature</li></ul></td></tr><tr><td style="vertical-align:top"><p>Injury, poisoning and procedural complications</p></td><td style="vertical-align:top"><p>Rare</p><ul><li>&nbsp; Radiation toxicity (see section 4.5)</li><li>&nbsp; Radiation recall</li></ul></td></tr></tbody></table><p>&nbsp;</p><p><em><u>Combination use in breast cancer</u></em></p><p>The frequency of grade 3 and 4 haematological toxicities, particularly neutropaenia, increases when gemcitabine is used in combination with paclitaxel. However, the increase in these adverse reactions is not associated with an increased incidence of infections or haemorrhagic events. Fatigue and febrile neutropaenia occur more frequently when gemcitabine is used in combination with paclitaxel. Fatigue, which is not associated with anaemia, usually resolves after the first cycle.</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="5" style="vertical-align:top"><p>Grade 3 and 4 Adverse Events</p><p>Paclitaxel versus gemcitabine plus paclitaxel</p><p>&nbsp;</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p>Number (%) of Patients</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Paclitaxel arm<br />(N=259)</p></td><td colspan="2" style="vertical-align:top"><p>Gemcitabine plus Paclitaxel arm (N=262)</p></td></tr><tr><td style="vertical-align:top"><p>Grade 3</p></td><td style="vertical-align:top"><p>Grade 4</p></td><td style="vertical-align:top"><p>Grade 3</p></td><td style="vertical-align:top"><p>Grade 4</p></td></tr><tr><td style="vertical-align:top"><p>Laboratory</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anaemia</p></td><td style="vertical-align:top"><p>5 (1.9)</p></td><td style="vertical-align:top"><p>1 (0.4)</p></td><td style="vertical-align:top"><p>15 (5.7)</p></td><td style="vertical-align:top"><p>3 (1.1)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thrombocytopaenia</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>14 (5.3)</p></td><td style="vertical-align:top"><p>1 (0.4)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Neutropaenia</p></td><td style="vertical-align:top"><p>11 (4.2)</p></td><td style="vertical-align:top"><p>17 (6.6)*</p></td><td style="vertical-align:top"><p>82 (31.3)</p></td><td style="vertical-align:top"><p>45 (17.2)*</p></td></tr><tr><td style="vertical-align:top"><p>Non-laboratory</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Febrile neutropaenia</p></td><td style="vertical-align:top"><p>3 (1.2)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>12 (4.6)</p></td><td style="vertical-align:top"><p>1(0.4)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fatigue</p></td><td style="vertical-align:top"><p>3 (1.2)</p></td><td style="vertical-align:top"><p>1 (0.4)</p></td><td style="vertical-align:top"><p>15 (5.7)</p></td><td style="vertical-align:top"><p>2 (0.8)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea</p></td><td style="vertical-align:top"><p>5 (1.9)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>8 (3.1)</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Motor neuropathy</p></td><td style="vertical-align:top"><p>2(0.8)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>6(2.3)</p></td><td style="vertical-align:top"><p>1(0.4)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sensory neuropathy</p></td><td style="vertical-align:top"><p>9(3.5)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>14(5.3)</p></td><td style="vertical-align:top"><p>1(0.4)</p></td></tr></tbody></table><p>*Grade 4 neutropaenia lasting for more than 7 days occurred in 12.6% of patients in the combination arm and 5.0% of patients in the paclitaxel arm.&nbsp;</p><p>&nbsp;</p><p><em><u>Combination use in ovarian cancer</u></em></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="5" style="vertical-align:top"><p>Grade 3 and 4 Adverse Events</p><p>Carboplatin versus Gemcitabine plus carboplatin</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p>Number (%) of Patients</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Carboplatin arm</p><p>(N=174)</p></td><td colspan="2" style="vertical-align:top"><p>Gemcitabine plus carboplatin arm</p><p>(N=175)</p></td></tr><tr><td style="vertical-align:top"><p>Grade 3</p></td><td style="vertical-align:top"><p>Grade 4</p></td><td style="vertical-align:top"><p>Grade 3</p></td><td style="vertical-align:top"><p>Grade 4</p></td></tr><tr><td style="vertical-align:top"><p>Laboratory</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anaemia</p></td><td style="vertical-align:top"><p>10(5.7)</p></td><td style="vertical-align:top"><p>4(2.3)</p></td><td style="vertical-align:top"><p>39(22.3)</p></td><td style="vertical-align:top"><p>9(5.1)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Neutropaenia</p></td><td style="vertical-align:top"><p>19(10.9)</p></td><td style="vertical-align:top"><p>2(1.1)</p></td><td style="vertical-align:top"><p>73(41.7)</p></td><td style="vertical-align:top"><p>50(28.6)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thrombocytopaenia</p></td><td style="vertical-align:top"><p>18(10.3)</p></td><td style="vertical-align:top"><p>2(1.1)</p></td><td style="vertical-align:top"><p>53(30.3)</p></td><td style="vertical-align:top"><p>8(4.6)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Leucopaenia</p></td><td style="vertical-align:top"><p>11(6.3)</p></td><td style="vertical-align:top"><p>1(0.6)</p></td><td style="vertical-align:top"><p>84(48.0)</p></td><td style="vertical-align:top"><p>9(5.1)</p></td></tr><tr><td style="vertical-align:top"><p>Non-laboratory</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Haemorrhage</p></td><td style="vertical-align:top"><p>0(0.0)</p></td><td style="vertical-align:top"><p>0(0.0)</p></td><td style="vertical-align:top"><p>3(1.8)</p></td><td style="vertical-align:top"><p>(0.0)</p></td></tr><tr><td style="vertical-align:top"><p>Febrile neutropaenia</p></td><td style="vertical-align:top"><p>0(0.0)</p></td><td style="vertical-align:top"><p>0(0.0)</p></td><td style="vertical-align:top"><p>2(1.1)</p></td><td style="vertical-align:top"><p>(0.0)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Infection without</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; neutropaenia</p></td><td style="vertical-align:top"><p>0(0)</p></td><td style="vertical-align:top"><p>0(0.0)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>(0.0)</p></td><td style="vertical-align:top"><p>1(0.6)</p></td></tr></tbody></table><p>Sensory neuropathy was also more frequent in the combination arm than with single agent carboplatin</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions </u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed below.</p><p>&nbsp;</p><p>Please report adverse drug events to:</p><p>The National Pharmacovigilance Centre (NPC):</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no known antidote for overdose of gemcitabine. Doses as high as 5700&nbsp;mg/m<sup>2 </sup>have been administered by intravenous infusion over 30‑minutes every 2 weeks with clinically acceptable toxicity. In the event of suspected overdose, the patient should be monitored with appropriate blood counts and receive supportive therapy, as necessary.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: pyrimidine analogues ATC code: L01BC05</p><p>&nbsp;</p><p><u>Cytotoxic activity in cell cultures</u></p><p>Gemcitabine shows significant cytotoxic effects against a variety of cultured murine and human tumour cells. Its action is phase-specific such that gemcitabine primarily kills cells that are undergoing DNA synthesis (S‑phase) and, under certain circumstances, blocks the progression of cells at the junction of the G<sub>1</sub>/S phase boundary. In vitro, the cytotoxic effect of gemcitabine is dependent on both concentration and time.</p><p>&nbsp;</p><p><u>Antitumoral activity in preclinical models</u></p><p>In animal tumour models, antitumoural activity of gemcitabine is schedule-dependent. When gemcitabine is administered daily, high mortality among the animals but minimal antitumoural activity is observed. If, however, gemcitabine is given every third or fourth day, it can be administered in non-lethal doses with substantial antitumoural activity against a broad spectrum of mouse tumours.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Cellular metabolism and mechanism of action: Gemcitabine (dFdC), which is a pyrimidine antimetabolite, is metabolised intracellularly by nucleoside kinase to the active diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleosides. The cytotoxic effect of gemcitabine is due to inhibition of DNA synthesis by two mechanisms of action by dFdCDP and dFdCTP. First, dFdCDP inhibits ribonucleotide reductase, which is uniquely responsible for catalysing the reactions that produce deoxynucleoside triphosphates (dCTP) for DNA synthesis. Inhibition of this enzyme by dFdCDP reduces the concentration of deoxynucleosides in general and, in particular, dCTP. Second, dFdCTP competes with dCTP for incorporation into DNA (self-potentiation).</p><p>&nbsp;</p><p>Likewise, a small amount of gemcitabine may also be incorporated into RNA. Thus, the reduced intracellular concentration of dCTP potentiates the incorporation of dFdCTP into DNA. DNA polymerase epsilon lacks the ability to eliminate gemcitabine and to repair the growing DNA strands. After gemcitabine is incorporated into DNA, one additional nucleotide is added to the growing DNA strands. After this addition there is essentially a complete inhibition in further DNA synthesis (masked chain termination). After incorporation into DNA, gemcitabine appears to induce the programmed cell death process known as apoptosis.</p><p>&nbsp;</p><p><u>Clinical data</u></p><p>&nbsp;</p><p><em><u>Pancreatic cancer</u></em></p><p>In a randomised phase III study of 126 patients with advanced or metastatic pancreatic cancer, gemcitabine showed a statistically significant higher clinical benefit response rate than 5-fluorouracil (23.8% and 4.8% respectively, p=0.0022). Also, a statistically significant prolongation of the time to progression from 0.9 to 2.3 months (log-rank p&lt;0.0002) and a statistically significant prolongation of median survival from 4.4 to 5.7 months (log-rank p&lt;0.0024) was observed in patients treated with gemcitabine compared to patients treated with 5-fluorouracil.</p><p>&nbsp;</p><p><em><u>Non small cell lung cancer</u></em></p><p>In a randomised phase III study of 522 patients with inoperable, locally advanced or metastatic NSCLC, gemcitabine in combination with cisplatin showed a statistically significant higher response rate than cisplatin alone (31.0% and 12.0%, respectively, p&lt;0.0001). A statistically significant prolongation of the time to progression, from 3.7 to 5.6 months (log-rank p&lt;0.0012) and a statistically significant prolongation of median survival from 7.6 months to 9.1 months (log-rank p&lt;0.004) was observed in patients treated with gemcitabine/cisplatin compared to patients treated with cisplatin.</p><p>In another randomised phase III study of 135 patients with stage IIIB or IV NSCLC, a combination of gemcitabine and cisplatin showed a statistically significant higher response rate than a combination of cisplatin and etoposide (40.6% and 21.2%, respectively, p=0.025). A statistically significant prolongation of the time to progression, from 4.3 to 6.9 months (p=0.014) was observed in patients treated with gemcitabine/cisplatin compared to patients treated with etoposide/cisplatin.</p><p>In both studies it was found that tolerability was similar in the two treatment arms.</p><p>&nbsp;</p><p><em><u>Ovarian carcinoma</u></em></p><p>In a randomised phase III study, 356 patients with advanced epithelial ovarian carcinoma who had relapsed at least 6 months after completing platinum based therapy were randomised to therapy with gemcitabine and carboplatin (GCb), or carboplatin (Cb). A statistically significant prolongation of the time to progression of disease, from 5.8 to 8.6 months (log-rank p= 0.0038) was observed in the patients treated with GCb compared to patients treated with Cb. Differences in response rate of 47.2% in the GCb arm versus 30.9% in the Cb arm (p=0.0016) and median survival 18 months (GCb) versus 17.3 (Cb) (p=0.73) favoured the GCb arm.</p><p>&nbsp;</p><p><em><u>Breast cancer</u></em></p><p>In a randomised phase III study of 529 patients with inoperable, locally recurrent or metastatic breast cancer with relapse after adjuvant/neoadjuvant chemotherapy, gemcitabine in combination with paclitaxel showed a statistically significant prolongation of time to documented disease progression from 3.98 to 6.14 months (log-rank p=0.0002) in patients treated with gemcitabine/paclitaxel compared to patients treated with paclitaxel. After 377 deaths, the overall survival was 18.6 months versus 15.8 months (log rank p=0.0489, HR 0.82) in patients treated with gemcitabine/paclitaxel compared to patients treated with paclitaxel and the overall response rate was 41.4% and 26.2% respectively (p= 0.0002).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics of gemcitabine have been examined in 353 patients in seven studies. The 121 women and 232 men ranged in age from 29 to 79 years. Of these patients, approximately 45% had non‑small cell lung cancer and 35% were diagnosed with pancreatic cancer. The following pharmacokinetic parameters were obtained for doses ranging from 500 to 2,592&nbsp;mg/m<sup>2 </sup>that were infused from 0.4 to 1.2 hours.</p><p>&nbsp;</p><p>Peak plasma concentrations (obtained within 5 minutes of the end of the infusion) were 3.2 to 45.5&nbsp;&micro;g/ml. Plasma concentrations of the parent compound following a dose of 1,000&nbsp;mg/m<sup>2</sup>/30‑minutes are greater than 5&nbsp;&micro;g/ml for approximately 30‑minutes after the end of the infusion, and greater than 0.4&nbsp;&micro;g/ml for an additional hour.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>The volume of distribution of the central compartment was 12.4&nbsp;l/m<sup>2</sup> for women and 17.5&nbsp;l/m<sup>2</sup> for men (inter‑individual variability was 91.9%). The volume of distribution of the peripheral compartment was 47.4&nbsp;l/m<sup>2</sup>. The volume of the peripheral compartment was not sensitive to gender.</p><p>The plasma protein binding was considered to be negligible.</p><p>Half‑life: This ranged from 42 to 94 minutes depending on age and gender. For the recommended dosing schedule, gemcitabine elimination should be virtually complete within 5 to 11 hours of the start of the infusion. Gemcitabine does not accumulate when administered once weekly.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Gemcitabine is rapidly metabolised by cytidine deaminase in the liver, kidney, blood and other tissues. Intracellular metabolism of gemcitabine produces the gemcitabine mono, di and triphosphates (dFdCMP, dFdCDP and dFdCTP) of which dFdCDP and dFdCTP are considered active. These intracellular metabolites have not been detected in plasma or urine. The primary metabolite, 2&#39;‑deoxy‑2&#39;, 2&#39;‑difluorouridine (dFdU), is not active and is found in plasma and urine.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>Systemic clearance ranged from 29.2&nbsp;l/hr/m<sup>2</sup> to 92.2&nbsp;/hr/m<sup>2</sup> depending on gender and age (inter‑individual variability was 52.2%). Clearance for women is approximately 25% lower than the values for men. Although rapid, clearance for both men and women appears to decrease with age. For the recommended gemcitabine dose of 1000&nbsp;mg/m<sup>2</sup> given as a 30‑minute infusion, lower clearance values for women and men should not necessitate a decrease in the gemcitabine dose.</p><p>Urinary excretion: Less than 10% is excreted as unchanged drug.</p><p>Renal clearance was 2 to 7&nbsp;l/hr/m<sup>2</sup>.</p><p>&nbsp;</p><p>During the week following administration, 92 to 98% of the dose of gemcitabine administered is recovered, 99% in the urine, mainly in the form of dFdU and 1% of the dose is excreted in faeces.</p><p>&nbsp;</p><p><u>dFdCTP kinetics</u></p><p>This metabolite can be found in peripheral blood mononuclear cells and the information below refers to these cells. Intracellular concentrations increase in proportion to gemcitabine doses of 35‑350&nbsp;mg/ m<sup>2</sup>/30‑minutes, which give steady state concentrations of 0.4‑5&nbsp;&micro;g/ml. At gemcitabine plasma concentrations above 5&nbsp;&micro;g/ml, dFdCTP levels do not increase, suggesting that the formation is saturable in these cells.</p><p>Half‑life of terminal elimination: 0.7‑12 hours.</p><p>&nbsp;</p><p><u>dFdU kinetics<br />Peak plasma concentrations (3‑15 minutes after end of 30‑minute infusion, 1000&nbsp;mg/m<sup>2</sup>): 28‑52&nbsp;&micro;g/ml.&nbsp; Trough concentration following once weekly dosing: 0.07‑1.12&nbsp;&micro;g/ml, with no apparent accumulation.&nbsp; Triphasic plasma concentration versus time curve, mean half‑life of terminal phase ‑ 65 hours (range 33‑84 hr).</u></p><p>Formation of dFdU from parent compound: 91%‑98%.</p><p>Mean volume of distribution of central compartment: 18&nbsp;l/m<sup>2</sup> (range 11‑22&nbsp;l/m<sup>2</sup>).</p><p>Mean steady state volume of distribution (Vss): 150 l/m<sup>2</sup> (range&nbsp;96‑228&nbsp;l/m<sup>2</sup>).</p><p>Tissue distribution: Extensive.</p><p>Mean apparent clearance: 2.5 l/hr/m<sup>2</sup> (range 1‑4&nbsp;l/hr/m<sup>2</sup>).</p><p>Urinary excretion: All.</p><p>&nbsp;</p><p><u>Gemcitabine and paclitaxel combination therapy</u></p><p>Combination therapy did not alter the pharmacokinetics of either gemcitabine or paclitaxel.</p><p><u>&nbsp;</u></p><p><u>Gemcitabine and carboplatin combination therapy</u></p><p>When given in combination with carboplatin the pharmacokinetics of gemcitabine were not altered</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>Mild to moderate renal insufficiency (GFR from 30 ml/min to 80 ml/min) has no consistent, significant effect on gemcitabine pharmacokinetics<em>.</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In repeat-dose studies of up to 6 months in duration in mice and dogs, the principal finding was schedule and dose-dependent haematopoietic suppression which was reversible.</p><p>&nbsp;</p><p>Gemcitabine is mutagenic in an <em>in vitro</em> mutation test and an <em>in vivo </em>bone marrow micronucleus test. Long term animal studies evaluating the carcinogenic potential have not been performed.</p><p>&nbsp;</p><p>In fertility studies, gemcitabine caused reversible hypospermatogenesis in male mice. No effect on the fertility of females has been detected.</p><p>&nbsp;</p><p>Evaluation of experimental animal studies has shown reproductive toxicity e.g. birth defects and other effects on the development of the embryo or foetus, the course of gestation or peri- and postnatal development.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Gemzar 200 mg contains:</u></p><p>Mannitol (E421)</p><p>Sodium acetate (E262)</p><p>Hydrochloric acid (E507) (for pH adjustment)</p><p>Sodium hydroxide (E524) (for pH adjustment)</p><p>&nbsp;</p><p><u>Gemzar 1000 mg contains</u></p><p>Mannitol (E421)</p><p>Sodium acetate (E262)</p><p>Hydrochloric acid (E507) (for pH adjustment)</p><p>Sodium hydroxide (E524) (for pH adjustment)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened vials: 3 years. 
Reconstituted solution:  
Chemical and physical in-use stability has been demonstrated for 24 hours at 30C. From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at room temperature, unless reconstitution (and further dilution, if applicable) has taken place in controlled and validated aseptic conditions. 
Solutions of reconstituted gemcitabine should not be refrigerated, as crystallisation may occur.  

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Unopened vial: Store below 30&deg;C</p><p>For storage conditions of the reconstituted medicinal product, see section 6.3</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Type I flint glass vials, with a rubber stopper and sealed with an aluminium seal, combined with a polypropylene cap.</p><p>Each pack contains 1 vial<strong>.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>GEMZAR is a hazardous drug.<u> </u></p><p><u>Handling</u></p><p>The normal safety precautions for cytostatic agents must be observed when preparing and disposing of the infusion solution. Handling of the solution for infusion should be done in a safety box and protective coats and gloves should be used. If no safety box is available, the equipment should be supplemented with a mask and protective glasses.</p><p>If the preparation comes into contact with the eyes, this may cause serious irritation. The eyes should be rinsed immediately and thoroughly with water. If there is lasting irritation, a doctor should be consulted. If the solution is spilled on the skin, rinse thoroughly with water.</p><p>&nbsp;</p><p><u>Instructions for reconstitution (and further dilution, if performed)</u></p><p>The only approved diluent for reconstitution of gemcitabine sterile powder is sodium chloride 9&nbsp;mg/ml (0.9%) solution for injection (without preservative). Due to solubility considerations, the maximum concentration for gemcitabine upon reconstitution is 40&nbsp;mg/ml. Reconstitution at concentrations greater than 40&nbsp;mg/ml may result in incomplete dissolution and should be avoided. &nbsp;</p><p>&nbsp;</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use aseptic technique during the reconstitution and any further dilution of gemcitabine for intravenous infusion administration.</p><p>&nbsp;</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To reconstitute, add 5&nbsp;ml of sterile sodium chloride 9&nbsp;mg/ml (0.9&nbsp;%) solution for injection, without preservative, to the 200&nbsp;mg vial or 25 ml sterile sodium chloride 9&nbsp;mg/ml (0.9&nbsp;%) solution for injection, without preservative, to the 1000&nbsp;mg vial. The total volume after reconstitution is 5.26&nbsp;ml (200&nbsp;mg vial) or 26.3&nbsp;ml (1000&nbsp;mg vial) respectively. This yields a gemcitabine concentration of 38&nbsp;mg/ml, which includes accounting for the displacement volume of the lyophilised powder. Shake to dissolve. Further dilution with sterile sodium chloride 9&nbsp;mg/ml (0.9&nbsp;%) solution for injection, without preservative can be done.&nbsp;&nbsp; Reconstituted solution is a clear colourless to light straw-coloured solution. &nbsp;</p><p>&nbsp;</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Parenteral medicinal products should be inspected visually for particulate matter and discolouration prior to administration. If particulate matter is observed, do not administer.</p><p>&nbsp;</p><p>Any unused product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lilly France, 24 boulevard Vital Bouhot, CS 500014, 92521 Neuilly sur Seine Cedex, France
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                15 February 2022

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>